ArticleEuropean journal of medical research2026
The comparative efficacy of SGLT-2 inhibitors and GLP-1 receptor agonists on metabolic benefits in T2DM patients: a systematic review and network meta-analysis.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSGLT-2 inhibitors and GLP-1 receptor agonists exhibit metabolic benefits on improving obesity, diabetes, hypertension and hyperlipidemia, but the differences between them remain unclear. We evaluated the comparative efficacy of these two agents on metabolic benefits in adults with T2DM.
methodThis study has searched the electronic databases from the inception of the databases up to March 30, 2025. Primary outcome was the efficacy for weight loss. Secondary outcomes included the effectiveness for HbA
results168 RCTs of 72,195 adults were deemed eligible. For losing weight, GLP-1 receptor agonists were more effective than SGLT-2 inhibitors (MD - 1.08 kg,95% CrI: - 1.78 to -0.36). In subgroup analyses, compared to SGLT-2 inhibitors, GLP-1 receptor agonists displayed a stronger weight-loss effect in subgroup of 30 kg/m
conclusionBoth GLP-1 receptor agonists and SGLT-2 inhibitors have been shown to confer metabolic benefits. GLP-1 receptor agonists displayed stronger effects on weight reduction for patients with obesity (BMI ≥ 30 kg/m REGISTRATION NUMBER: CRD42021247584. The name of the registry: PROSPERO. The URL to the registration: https://www.crd.york.ac.uk/PROSPERO/ .
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.